Key facts
- What it is: Teduglutide is a long-acting analog of glucagon-like peptide-2 used in selected adults and children with short bowel syndrome who depend on parenteral support.
- Evidence: Strong human evidence for short bowel syndrome with intestinal failure.
- Status: FDA-approved GLP-2 analog.
- Main caution: Because teduglutide promotes mucosal growth, monitoring addresses intestinal polyps and neoplasia, obstruction, biliary or pancreatic disease, fluid overload, and altered absorption of other medicines..
- Sources: 5 PubMed-indexed papers linked below.
What is Teduglutide?
Teduglutide is a long-acting analog of glucagon-like peptide-2 used in selected adults and children with short bowel syndrome who depend on parenteral support. It promotes intestinal adaptation. It is not a weight-loss GLP-1 drug despite the similar acronym.
The first SEO trap with peptide content is treating every compound as if it belongs to the same category. It does not. Some peptides are approved prescription medicines supported by randomized trials; others are endogenous signaling molecules being studied in cells; others are unapproved chemicals sold with no regulated manufacturing chain. For Teduglutide, the evidence and regulatory category above determine what conclusions are reasonable.
This guide does not provide a dose, cycle, protocol, source, or personal recommendation. It translates published research so readers can distinguish a measured result from a marketing claim and bring better questions to a licensed clinician.
How does Teduglutide work?
GLP-2 acts on the gut to support mucosal growth, blood flow, barrier function, and nutrient absorption. Teduglutide resists DPP-4 breakdown, extending activity. Better absorption can allow carefully supervised reductions in intravenous fluids or nutrition for some patients.
Mechanism is not the same as clinical benefit. A compound can activate a receptor, change a biomarker, or improve an animal model without improving how people feel, function, or survive. The strongest medical claims require controlled human outcomes, not a plausible pathway alone.
What does the research on Teduglutide show?
Randomized trials found that more patients receiving teduglutide achieved meaningful reductions in parenteral-support volume than those receiving placebo. Extension and pediatric studies show that responses can deepen over time, while some patients remain dependent on support.
These papers were selected to show the shape of the evidence: foundational biology, clinical trials where they exist, safety signals, and reviews that place single studies in context. A citation does not mean PepMate endorses a treatment; it lets readers inspect the original record.
How strong is the evidence?
Evidence assessment: Strong human evidence for short bowel syndrome with intestinal failure. Short bowel anatomy, remaining colon, baseline support, and adaptation differ substantially. Trial success means reduced support, not guaranteed independence or restoration of normal intestine.
Evidence strength depends on study design, directness, replication, sample size, and whether researchers measured a meaningful outcome. Animal evidence can justify a human trial, but it cannot establish a human treatment. Observational human data can identify associations, but it cannot reliably prove cause and effect.
Is Teduglutide approved or available?
FDA-approved GLP-2 analog. Approval is tied to a specific product, indication, population, formulation, and regulator. “Research use only,” clinic availability, compounding, or a listing on a peptide website is not the same as approval. Availability can change, so current regulator labeling and professional guidance take priority over any static article.
Teduglutide safety, risks, and evidence gaps
Because teduglutide promotes mucosal growth, monitoring addresses intestinal polyps and neoplasia, obstruction, biliary or pancreatic disease, fluid overload, and altered absorption of other medicines.
Short bowel anatomy, remaining colon, baseline support, and adaptation differ substantially. Trial success means reduced support, not guaranteed independence or restoration of normal intestine.
Unapproved online peptides add risks that a paper about a verified laboratory compound cannot measure: mislabeling, contamination, sterility failure, degradation, and a concentration different from the label. Even an endogenous or short peptide can cause harm when the route, exposure, or manufacturing quality changes.
Frequently asked questions
What is Teduglutide?
Teduglutide is a long-acting analog of glucagon-like peptide-2 used in selected adults and children with short bowel syndrome who depend on parenteral support. It promotes intestinal adaptation. It is not a weight-loss GLP-1 drug despite the similar acronym.
How does Teduglutide work?
GLP-2 acts on the gut to support mucosal growth, blood flow, barrier function, and nutrient absorption. Teduglutide resists DPP-4 breakdown, extending activity. Better absorption can allow carefully supervised reductions in intravenous fluids or nutrition for some patients.
Is Teduglutide FDA-approved?
FDA-approved GLP-2 analog. Approval is indication-specific and can differ by country; check current regulator labeling rather than relying on peptide-shop descriptions.
What does PubMed research on Teduglutide show?
Randomized trials found that more patients receiving teduglutide achieved meaningful reductions in parenteral-support volume than those receiving placebo. Extension and pediatric studies show that responses can deepen over time, while some patients remain dependent on support.
What are the main risks of Teduglutide?
Because teduglutide promotes mucosal growth, monitoring addresses intestinal polyps and neoplasia, obstruction, biliary or pancreatic disease, fluid overload, and altered absorption of other medicines.
PubMed sources
Every medical claim in this guide is anchored to peer-reviewed or scholarly literature indexed on PubMed. Open the abstracts below to review the study design, population, and limitations.
- Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. — PubMed 22982184 (2012)
- Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. — PubMed 16099790 (2005)
- Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. — PubMed 21317170 (2011)
- Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. — PubMed 26844839 (2016)
- Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome. — PubMed 27855998 (2017)
Source selection and update method: PepMate Research Editorial Policy. Last updated 22 July 2026.